Separate Episodes of Delirium Associated With Levetiracetam and Amiodarone Treatment in an Elderly Woman

被引:9
作者
Foley, Kevin T. [1 ,2 ]
Bugg, Karen S. [2 ]
机构
[1] Michigan State Univ, Coll Human Med, Dept Neurol & Ophthalmol, Clin Ctr B110, E Lansing, MI 48824 USA
[2] St Marys Hlth Care, Dept Neurosci, Grand Rapids, MI USA
关键词
levetiracetam; amiodarone; delirium; confusion; elderly; ANTICHOLINERGIC ACTIVITY; NEUROTOXICITY; EPILEPSY; THERAPY; OLDER; MEDICATIONS; PSYCHOSIS; SEIZURES; ADULTS;
D O I
10.1016/j.amjopharm.2010.03.001
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: Delirium related to levetiracetam has not been previously described in the literature and is infrequently associated with amiodarone. Objective: The aim of this report was to discuss the possibility that administration of levetiracetam and amiodarone may precipitate delirium in some elderly patients. Case summary: An 80-year-old white woman with levothyroxine-treated hypothyroidism developed acute confusion and paranoia 5 days after substituting levetiracetam 1000 mg orally twice daily for phenytoin 100 mg orally twice daily to control new, generalized seizures. Before starting levetiracetam treatment, results of the patient's blood and urine tests, brain magnetic resonance imaging, and cerebrospinal fluid examination were within normal limits. Delirium from levetiracetam was suspected. Therefore, the dosage was titrated downward to allow discontinuation of the drug; levetiracetam was replaced with pregabalin 150 mg twice daily. Subsequent improvement in mental status occurred within 14 days after administration of the last dose of levetiracetam. Three months later, the patient developed symptomatic atrial fibrillation, which was treated with cardioversion, followed by oral amiodarone 400 mg twice daily for 10 days and then 200 mg once daily for 3 months. Within 1 to 2 weeks after starting amiodarone, she developed changes in cognition consistent with delirium. Computed tomography of the brain showed no acute changes, and blood test results were within normal limits with the exception of a serum free thyroxine level of 2.06 ng/dL and a suppressed but measurable serum thyroid-stimulating hormone level (0.13 mu IU/mL). No improvement was noted after reduction of the dose of levothyroxine from 0.1 mg to 0.075 mg daily. Two weeks after amiodarone was discontinued, her mental status had returned to baseline levels. Based on a score of 6 (probable) for each medication using the Naranjo scale, the 2 episodes of delirium were probably related to levetiracetam and amiodarone. Conclusion: This case report describes separate episodes of delirium probably related to treatment with levetiracetam and amiodarone in an elderly patient. (Am J Geriatr Pharmacother. 2010;8:170-174) (C) 2010 Excerpta Medica Inc.
引用
收藏
页码:170 / 174
页数:5
相关论文
共 33 条
[1]   Benefit-risk assessment of levetiracetam in the treatment of partial seizures [J].
Abou-Khalil, B .
DRUG SAFETY, 2005, 28 (10) :871-890
[2]  
[Anonymous], KEPPR LEV PACK INS
[3]   Amiodarone-induced delirium [J].
Athwal, H ;
Murphy, G ;
Chun, S .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 11 (06) :696-697
[4]  
Barry JJ, 1999, AM J PSYCHIAT, V156, P1119
[5]   Amiodarone and the thyroid [J].
Basaria, S ;
Cooper, DS .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (07) :706-714
[6]   Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs [J].
Bergey, GK .
EPILEPSIA, 2005, 46 :161-168
[7]   FREQUENT NEUROLOGIC TOXICITY ASSOCIATED WITH AMIODARONE THERAPY [J].
CHARNESS, ME ;
MORADY, F ;
SCHEINMAN, MM .
NEUROLOGY, 1984, 34 (05) :669-671
[8]   Anticholinergic activity of 107 medications commonly used by older adults [J].
Chew, Marci L. ;
Mulsant, Benoit H. ;
Pollock, Bruce G. ;
Lehman, Mark E. ;
Greenspan, Andrew ;
Mahmoud, Ramy A. ;
Kirshner, Margaret A. ;
Sorisio, Denise A. ;
Bies, Robert R. ;
Gharabawi, Georges .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (07) :1333-1341
[9]  
COHEN-ARMON M, 1984, J CARDIOVASC PHARM, V6, P1148
[10]   A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials [J].
Cramer, JA ;
De Rue, K ;
Devinsky, O ;
Edrich, P ;
Trimble, MR .
EPILEPSY & BEHAVIOR, 2003, 4 (02) :124-132